A phase i study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study

D. Scott McMeekin, Michael W. Sill, Joan L. Walker, Kathleen N. Moore, Steven E. Waggoner, Premal H. Thaker, Tina Rizack, James S. Hoffman, Paula M. Fracasso

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Objective To determine the maximum tolerated dose (MTD) of a modified paclitaxel/doxorubicin/cisplatin (TAP) regimen which incorporated intraperitoneal (IP) paclitaxel or IP paclitaxel/cisplatin in advanced endometrial cancer. Methods Patients (pts) with FIGO (1998) Stage IIIA/IIIC with positive cytologic washings/ascites, adnexa, or serosa or Stage IV (intraperitoneal disease spread), histologically confirmed endometrial cancer were eligible. The study was designed as a phase I, 3 + 3 dose escalation study evaluating 5 dose levels (DL). All pts received cycles 1-2 with IV TAP, and cycles 3-6 with IV/IP therapy, on a 21 day schedule. Adverse events were evaluated on cycles 3-4 for dose limiting toxicity (DLT) and dose escalation decisions. Results Twenty-one pts were enrolled, of which 17 were evaluable for DLT. Most pts had Stage IV disease (76%) and serous/clear cell histology (59%). The MTD was determined to be DL 3 (cycles 3-6 including paclitaxel 90 mg/m2 IP, doxorubicin 45 mg/m2 IV, cisplatin 50 mg/m2). Three DLT events occurred and were related to grades 3-4 metabolic toxicities. There was one grade 2 sensory neuropathy event and myelosupression was tolerable without the use of G-CSF. 88% of evaluable pts completed 6 cycles of therapy. With a median follow-up of 22 months, 46% of patients remain progression-free at 2 years. Conclusion We described an IV/IP based modification of a standard TAP regimen in endometrial cancer. Based on the high rate of completing 6 cycles of therapy, low rates of neuropathy, and promising PFS, further study of IP therapy in endometrial cancer is warranted.

Original languageEnglish
Pages (from-to)36-40
Number of pages5
JournalGynecologic oncology
Volume138
Issue number1
DOIs
StatePublished - Jul 1 2015

Keywords

  • Cisplatin
  • Doxorubicin plus intraperitoneal
  • Endometrial cancer patients
  • NRG Oncology

Fingerprint

Dive into the research topics of 'A phase i study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study'. Together they form a unique fingerprint.

Cite this